Funds and ETFs Incyte Corporation

INCY

US45337C1027

Name	Weight	AuM	1st Jan change	Investor Rating
LYXOR MSCI USA ESG LEADERS EXTRA (DR) UCITS ETF - ACC - USD	0.06%	330 M€	-.--%
LEVERAGE SHARES 3X LONG TOTAL WORLD ETP SECURITIES - USD	0.05%	0 M€	0.00%	-
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A - EUR HEDGED	0.05%	8 M€	+5.74%	-
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A (EUR) - EUR	0.05%	744 M€	+8.55%
REVERE SECTOR OPPORTUNITY ETF - USD	0.05%	6 M€	+17.98%	-
AGILITY SHARES MANAGED RISK ETF - USD	0.05%	121 M€	+6.79%	-
AMUNDI MSCI WORLD ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.04%	276 M€	+11.40%	-
CSIF (IE) MSCI USA BLUE UCITS ETF B ACC - USD	0.04%	2,517 M€	+12.10%	-
NEXT FUNDS S&P 500 (UNHEDGED) ETF - JPY	0.04%	57 M€	+20.49%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.03%	283 M€	+19.39%
HSBC MSCI USA UCITS ETF - USD	0.03%	34 M€	+11.62%	-
LYXOR NET ZERO 2050 S&P 500 CLIMATE PAB (DR) UCITS ETF - DAILY HEDGED TO EUR - ACC - HEDGED EUR	0.03%	273 M€	-.--%
LYXOR NET ZERO 2050 S&P 500 CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.03%	655 M€	-.--%	-
LYXOR NET ZERO 2050 S&P 500 CLIMATE PAB (DR) UCITS ETF - DIST - USD	0.03%	1,174 M€	+23.54%
LYXOR NET ZERO 2050 S&P WORLD CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.02%	205 M€	-.--%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.02%	391 M€	+8.49%	-
NIGHTSHARES 500 1X/1.5X ETF - USD	0.02%	14 M€	+16.19%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR ETF - USD	0.02%	571 M€	+6.88%	-
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.02%	206 M€	-.--%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	34 M€	+8.28%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.02%	284 M€	-.--%
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.02%	607 M€	+0.05%	-
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.02%	1,166 M€	+0.26%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - USD	0.02%	23 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - EUR	0.02%	786 M€	-.--%

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

2024-05-15 - BofA Securities Health Care Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.6 USD

Average target price

73.35 USD

Spread / Average Target

+27.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-8.27%	12.93B
CSL LIMITED	-2.47%	89.37B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.65B
BIOGEN INC.	-12.92%	32.81B
UCB	+53.49%	25B
BIOMARIN PHARMACEUTICAL INC.	-16.51%	15.29B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.61B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.82%	11.49B
SWEDISH ORPHAN BIOVITRUM AB	+5.54%	8.98B
INNOVENT BIOLOGICS, INC.	-7.72%	8.23B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
57.6 ^USD	+8.56%		+6.51%	-8.27%

May. 13	Equities Close Mixed as Markets Weigh Consumer Inflation Survey	MT
May. 13	Equities Close Mixed as Markets Parse Consumer Inflation Survey	MT